{"name":"Aeovian Pharmaceuticals, Inc.","slug":"aeovian-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AV078","genericName":"AV078","slug":"av078","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"AV078","genericName":"AV078","slug":"av078","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOYko3NFdTdnpQZVI5MGVhVkxBbC16eWhPNGNraUgwcnhlNERoMXlfbzdrSEtJMkZ6MUUzd09fQ3Jiai00NkFRQ3EyWkVXU0I1VjZxZEJUUlNMTUJ1VEQ1NTZ1bG9OOGhZZWJLNHFGa1czaGZYb2gzZHZkRzNrOERCV3NneVE0UjZnZ3VnTU9jMnFDaldJcldHcE93WUcyM25pMGNMUk1rV3VKb0k?oc=5","date":"2026-04-07","type":"pipeline","source":"BioCentury","summary":"Precision mTOR targeting aims to widen the window in TSC epilepsy - BioCentury","headline":"Precision mTOR targeting aims to widen the window in TSC epilepsy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQV0ZVaFVVTjZnRFB1eFNXTXhWNUV0YnA0YzhaNHZ0WlQ0U3lrV29oQWxtRzRXQlNpUDZ2Y2hncWw3Snk5d2ZxaFVvdnZ4cEVfNHNKejR4MHQ3UFRsNld2VVh5aVk2WVlJclV1ZnFNSThmNUN0ZU5waWxNZnZ1TFhqUDNsVkIzMkZ3REVfWUdQVDBHVkZFNzJB?oc=5","date":"2026-01-12","type":"pipeline","source":"Clinical Leader","summary":"Working (Successfully) With Pharma: A PAG's Perspective - Clinical Leader","headline":"Working (Successfully) With Pharma: A PAG's Perspective","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQWE9ZWU9YUkFYNEQxcGN2YWhTV2VNM3VPMlJ5QjlxdUxtS2dCWTZobTRKVnZLWHBrbEZyRnp5Tk1aLTBIVjFpRUlLM2l6N0xoZFpwYTRPX2xQZlkzUVN6eDk5Ujh6aWNyMlBBbDA0dTU0RmFJazVrVXo4emJoNWpWV2pKWmI2QVJINldVOUFEOW9nTTZxTndVOGo0UkhodmFIejh4MQ?oc=5","date":"2026-01-06","type":"pipeline","source":"The Business Journals","summary":"'We've really got an opportunity': How a San Francisco area company aims to change the lives of epilepsy patients - The Business Journals","headline":"'We've really got an opportunity': How a San Francisco area company aims to change the lives of epilepsy patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxNTGVNeWNrd3RPaEIyU0F1VjNSLWhpRUNiYXZFZDk4cEsxU3lNVUstWXo4bXdlektvcnVxNExLaHpPRXZoWFc0ajVkUWY4aTZXdEhYbnQ5TGQxNnhIc2JWY1NScnYtUC1YMG0xUk5jN2dVbU9ZOU9HcHdEdFE1dDJheTkzOXRaaFRBSnRidXg0VXdyNmdpUlpsYXZvYURKZVF3ZnJBSGRlT2VSTGg3NVN4eGNXcXhwaFlma0xFcF9mQW4wdFR3SnJqYTF1T0txZXhjSWdtR0NCTzIzbFJhZWc1dVBxQ09oMjRYWHlad250TTF3ZG1IYXF2cjRCMnlfTm9kN1BHdEVUQXZzWWItREZDR0hhRGUtS29fWjBsbmhYWEZtN0Y2TWlfbFlB?oc=5","date":"2025-12-16","type":"pipeline","source":"Business Wire","summary":"Aeovian Pharmaceuticals Raises $55 Million to Advance First-in-Class Selective mTORC1 Inhibitor for Tuberous Sclerosis Complex-Related Epilepsy - Business Wire","headline":"Aeovian Pharmaceuticals Raises $55 Million to Advance First-in-Class Selective mTORC1 Inhibitor for Tuberous Sclerosis C","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE81Wm1uN19fQVY3ajc0T0JCai1FZWVUbTZQTVlydE1zQ2Z3TzdSSjBraEhhcGd6S014OE8tOE1Kb28xZmJMRVBiNEJ5RGNfQnJpUDlj?oc=5","date":"2025-12-16","type":"trial","source":"firstwordpharma.com","summary":"Aeovian nabs $55M to fund mid-stage epilepsy study - firstwordpharma.com","headline":"Aeovian nabs $55M to fund mid-stage epilepsy study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQdmcxZ09QTFI2TDg5dklod0IwTDlOYW1zcERhY2ZIMDhuNm1XQ1hYZnJkWFB4eWlENzlsVnZBclQ2dnhKNHE0SGVoOGEwTTdoX2tqYkRHVGVvazJuRmNqR245RHJRbnFrbkdPNDhmcmpxNnRObHRGajlRTGRtdjRvZ0xzdjhGOFQweWJ3RWhTUU00SlE0Qi1LU3BnR0I3R01Lb3BrTXdIVThjRkZBUURaX3RBVm5vcUVxaWs4?oc=5","date":"2025-10-14","type":"pipeline","source":"Inside Precision Medicine","summary":"Five Key Startups Shining the Light on Rare Diseases - Inside Precision Medicine","headline":"Five Key Startups Shining the Light on Rare Diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPRllkQU9GTUxScXhXc0t4NVVXaS1iQ0o3ZWEtQTJJNHBETW1sWVJDc295a0QteEc3T3YyUnhQLUtzMThpNmdDMjZWNUdEQVc3NGJ6WHIzQzhyUDFpcG90ZHJBdGZmSzNTWkJDbldMOFRZLWlITURvSjVIQlZxZms5bDI2R3o3MzlaNkRlbm1ldngxNzlXV2c0?oc=5","date":"2024-11-20","type":"patent","source":"bioworld.com","summary":"Aeovian Pharmaceuticals patents new CD38 inhibitors - bioworld.com","headline":"Aeovian Pharmaceuticals patents new CD38 inhibitors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTFBkTXBRV3MyalN4M1g5LVU5eGFNbkxOM1pfcndoc2NnZ2Z3Nnk0V0x6cVJHVWtYZFhMR1AydEdvMzhpZEJPQ2R5NWZNTGlUQTJOaDRBSmtwSnZNQWpPS0dGS2EwVm5qS1RYTXNqYkVEOU5yMW1qVE5udQ?oc=5","date":"2024-10-02","type":"pipeline","source":"PharmTech.com","summary":"European Biotech Targeting Anti-ageing - PharmTech.com","headline":"European Biotech Targeting Anti-ageing","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}